Regulus Therapeutics Inc. announced, after review of all available safety data, the Company initiated screening in the of the fourth cohort of patients in the Phase 1b MAD study of RGLS8429 for the treatment of ADPKD. Patients in the fourth cohort will receive an open label fixed dose of 300 mg of RGLS8429 every other week for three months. The study protocol has been amended to include up to 30 subjects in the fourth cohort in order to further examine potential impact on total kidney volume in patients with APDKD.

PC1 and PC2 are the protein products of the PKD1 and PKD2 genes respectively and have been shown to directly correlate with disease severity. The Company amended the protocol to include a fourth cohort of up to 30 subjects who will receive a fixed dose of 300 mg ofRGLS8429 administered every other week for three months".